Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate the Safety of OBP-301, Telomelysin in Combination With Radiation Therapy in Patients With Esophageal Cancer Not Applicable for Standard Therapy

Trial Profile

A Phase 1 Study to Evaluate the Safety of OBP-301, Telomelysin in Combination With Radiation Therapy in Patients With Esophageal Cancer Not Applicable for Standard Therapy

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Suratadenoturev (Primary)
  • Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Oncolys BioPharma
  • Most Recent Events

    • 10 Feb 2023 According to a Oncolys Biopharma media release, this trial is being conducted on the basis of orphan drug designation of Telomelysin for esophageal cancer in the U.S.
    • 18 Jun 2021 Results assessing the safety and clinical benefit of OBP-301 plus radiotherapy oesophageal cancer patients unfit for standard chemoradiation treatments, published in the European Journal of Cancer.
    • 24 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Jun 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top